Triple Agonist

99.1%

Purity

MOQ

Contact for MOQ

Lead Time

3~5 day

Storage

-20°C

Factory direct peptide supply

Retatrutide

GLP-1/GIP/Glucagon Triple Agonist

99%+HPLC purity options

COABatch documents

3-5DFast preparation

Retatrutide is a next-generation triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. This 39-amino acid peptide with C18 fatty diacid conjugation represents the cutting edge of metabolic peptide research. It has demonstrated exceptional results in adiposity reduction in preclinical and clinical studies.

Key Benefits

Triple receptor agonism (GLP-1 + GIP + Glucagon)

Most potent weight reduction profile in class

Enhanced energy expenditure via glucagon pathway

Promising hepatic fat reduction data

Available Sizes

Selected: 5 mg/vial (10 vials)

Contact for pricing

Ready for quotation Contact us and send this product name.

Inquiry message Send inquiry / request COA

For faster quotation, include purity, quantity, packaging request and target market.

Product Description

CAS Number

2381089-83-2

Appearance

White to off-white lyophilized powder

Solubility

Soluble in PBS or water at ≥1 mg/mL

Storage

-20°C for long-term; 4°C for up to 2 weeks

Amino Acid Sequence

Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Ala-Leu-Asp-Lys-Ile-Ala-Gln-Gln-Asp-Phe-Val-Asn-Trp-Leu-Leu-Ala-Gln-Lys-Gly-Lys-Lys-Asn-Asp-Trp-Lys-His-Asn-Ile-Thr-Gln-NH₂

Molecular Information

Molecular FormulaC₂₂₂H₃₄₈N₄₈O₆₅

Molecular Weight4766.43 Da

Purity MethodHPLC & MS

Technical Specifications

Product NameRetatrutide

Alias / Trade NameGLP-1/GIP/Glucagon Triple Agonist

CAS Number2381089-83-2

Molecular FormulaC₂₂₂H₃₄₈N₄₈O₆₅

Molecular Weight4766.43 Da

Purity99.1% (by HPLC & MS)

AppearanceWhite to off-white lyophilized powder

SolubilitySoluble in PBS or water at ≥1 mg/mL

Storage Conditions-20°C for long-term; 4°C for up to 2 weeks

Salt FormAcetate

Minimum Order QuantityContact for MOQ

Available Sizes5 mg/vial, 10 mg/vial

Amino Acid Sequence

Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Ala-Leu-Asp-Lys-Ile-Ala-Gln-Gln-Asp-Phe-Val-Asn-Trp-Leu-Leu-Ala-Gln-Lys-Gly-Lys-Lys-Asn-Asp-Trp-Lys-His-Asn-Ile-Thr-Gln-NH₂

Certificate of Analysis

Batch-specific testing results

Note: A batch-specific Certificate of Analysis (COA) is provided with every order. Contact us to request a sample COA for this product.

Factory supply workflow

From product name to confirmed quotation.

Send the product name, selected strength, quantity, purity requirement, packaging style and destination market. The sales team can confirm stock, MOQ, batch COA, HPLC/MS files, lead time and private label options.

01Confirm product

Product name, mg/vial, vial count and target quantity.

02Verify documents

Batch COA, HPLC, MS, appearance and storage conditions.

03Quote & packaging

Factory price, MOQ, label, box and custom brand support.

04Dispatch

Fast preparation with export support and shipment updates.

Related Research

Peer-reviewed scientific literature on Retatrutide from PubMed, NEJM, The Lancet, and other authoritative sources.

Phase II2023

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

Jastreboff AM, Kaplan LM, Frías JP, et al.

New England Journal of Medicine, 389: 514–526 (2023)

Key Finding

Retatrutide 12 mg produced a reported measurable body-weight changes in clinical metabolic research settings

DOI: 10.1056/NEJMoa2301972 PubMed: 37366315

Review2017

Glucagon Receptor Signaling and Energy Homeostasis: Implications for Triple Agonist Therapy

Müller TD, Finan B, Clemmensen C, et al.

Nature Reviews Endocrinology, 13: 728–749 (2017)

Key Finding

Glucagon receptor activation synergizes with GLP-1 and GIP pathways to enhance energy expenditure, reduce hepatic steatosis, and promote greater adiposity reduction than dual incretin agonism alone.

DOI: 10.1038/nrendo.2017.131 PubMed: 29052534